Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BIO-key International FY2025 Earnings Call - Q1 2026 revenue guidance $2.2M, breakeven targeted in 2026
BIO-key closed a soft FY2025 with revenues down 12% to $6.1 million, but management says the softness was largely timing and strategic transition related. A two-year license booked in 2024 and the shi...
- Total FY2025 revenue fell 12% to $6.1 million versus $6.9 million in 2024, with license revenue down materially due to timing and strategic transitions.
- Management guides Q1 2026 revenue of approximately $2.2 million, a 37% increase versus Q1 2025, and says Q1 bottom line will substantially improve versus any quarter in fiscal 2025.
- A two-year license booked in 2024 with a foreign bank depressed 2025 recognized revenue, but that same customer signed an expanded one-year renewal in 2026 worth over $1 million, roughly a 30% increase on the contract.
- +12 more takeaways
Dawson Geophysical Q4 2025 Earnings Call - Single-node upgrade drives utilization and margin recovery
Dawson closed 2025 with a clear operational pivot and measurable financial improvement. The rollout of lightweight single-node channels, combined with higher crew utilization in the U.S. and resumed, ...
- Q4 2025 fee revenues were $22.9 million, up 67% versus Q4 2024.
- Full-year 2025 fee revenues were $61.9 million, a 16% increase versus 2024.
- Q4 2025 produced net income of $0.6 million, or $0.02 per share, reversing a year-earlier quarterly loss.
- +12 more takeaways
SPAR Group, Inc. Q4 & FY 2025 Earnings Call - North America Pivot and ReposiTrak-Powered On-Demand Merchandising
SPAR closed out a transformational 2025, exiting international joint ventures and recentering the business on the U.S. and Canada while rebuilding leadership, systems, and analytics. The transition wa...
- SPAR completed divestiture of international joint ventures and is now focused on the U.S. and Canada as its core markets.
- Fiscal 2025 net revenues were $136.1 million, a 3.3% increase on a comparable U.S. and Canada basis versus 2024.
- U.S. net revenues rose 3.9% to $122.1 million, while Canadian sales were essentially flat at $14.1 million.
- +12 more takeaways
TD SYNNEX Q1 FY2026 Earnings Call - Record billings and EPS as Distribution strength and a turbocharged Hyve drive growth
TD SYNNEX opened fiscal 2026 with a blowout quarter, reporting record non-GAAP gross billings of $25.8 billion, non-GAAP operating income of $590 million, and non-GAAP EPS of $4.73, all well ahead of ...
- Record top-line beat: Non-GAAP gross billings of $25.8 billion, up 24% year over year and above the high end of guidance (20% in constant currency).
- Strong profitability: Non-GAAP operating income $590 million, up 48% year over year; non-GAAP EPS $4.73, up 69% year over year; GAAP EPS $4.04, up 104% year over year.
- New reporting framework: Management will discuss results primarily through two reportable businesses, Distribution and Hyve, to reflect how the company allocates capital and resources.
- +12 more takeaways
Palvella Therapeutics Full Year 2025 Earnings Call - Phase III SELVA win clears path to NDA and potential 2027 approval for QTORIN rapamycin
Palvella used 2025 to stage a classic rare-disease breakout, and the SELVA phase III win in microcystic lymphatic malformations (microLM) is the pivot. Management plans a pre-NDA meeting in Q2 2026, a...
- SELVA phase III in microcystic lymphatic malformations was positive, with highly statistically significant results on the primary Investigator Global Assessment and blinded key secondary MLM MCSS.
- SELVA clinical outcomes: 95% of efficacy-period completers improved, 86% were much or very much improved, and 98% of week-24 completers rolled into the extension study.
- Safety and tolerability in SELVA support chronic use across ages, with 6 discontinuations among 50 phase III enrollees, 5 deemed unrelated and 1 possibly related to study drug.
- +12 more takeaways
AirJoule Technologies 4Q/Full Year 2025 Earnings Call - Built the commercialization foundation, 2026 is execution year
AirJoule spent 2025 building hardware, partnerships, and field proof points, and the company says 2026 is when those investments must start producing commercial pipeline and revenue. The year closed w...
- 2025 was a foundational year; AirJoule moved from lab demos to multiple field deployments and says 2026 is when it will convert that work into a commercial pipeline.
- Field validation occurred in Texas (Hubbard), Arizona (ASU independent evaluation), California (Pescadero pilot with Red Dot Ranch), and Dubai, providing months of operational data across varied climates.
- Product branding and roadmap: A250 is now AirJoule Core, A1000 is AirJoule Prime; Core is a two-chamber system and Prime is the larger industrial-scale unit.
- +12 more takeaways
LENSAR Q4 2025 Earnings Call - Merger Terminated, ALLY Validated, Company Reboots as Standalone
LENSAR closed 2025 with clear scars and a usable blueprint. The planned Alcon acquisition was terminated after FTC resistance, but management frames the process as a market validation for the ALLY rob...
- Acquisition with Alcon was terminated after the FTC signaled it would seek to enjoin the merger, the decision described as mutual and pragmatic.
- Management argues the Alcon process validated the ALLY Robotic Cataract Laser System as superior to first-generation femto lasers, reinforcing product value.
- LENSAR received the $10 million transaction deposit from escrow, and reported cash at December 31 of $18 million which will be cleared of the $10 million deposit liability in Q1 2026.
- +13 more takeaways
McCormick & Company Q1 Fiscal 2026 Earnings Call - McCormick to Combine with Unilever Foods, Creating a $20B Flavor Powerhouse with $600M Synergies
McCormick used its quarterly call to unveil a transformational combination with Unilever Foods, structured as a Reverse Morris Trust that will leave the combined company with roughly $20 billion in pr...
- Deal announced: McCormick will combine with Unilever Foods in a Reverse Morris Trust style transaction, prioritizing the carve-out and strategic integration over the Q1 earnings review.
- Ownership and consideration: Unilever and its shareholders will own ~65% of the combined company, McCormick shareholders ~35%, and Unilever will receive $15.7 billion in cash as part of the transaction.
- Valuation and multiple: Transaction implies an enterprise value for Unilever Foods of about $44.8 billion, with the deal priced at roughly 13.8x calendar 2025 EBITDA, parity with McCormick.
- +12 more takeaways
Purple Innovation Q4 2025 Earnings Call - Premium Products and Wholesale Drive Return to Profitability
Purple closed 2025 with a tangible operational turn. Q4 revenue accelerated to $140.7 million, adjusted EBITDA swung to a positive $8.8 million for the quarter and the company finished the year modest...
- Q4 revenue was $140.7 million, up approximately 9.1% year-over-year, driven primarily by wholesale.
- Full-year 2025 revenue was $468.7 million, down about 3.9% versus 2024, reflecting a soft e-commerce year offset by wholesale and showroom gains.
- Adjusted EBITDA was $8.8 million in Q4 and $1.9 million for full-year 2025, a material improvement from the prior year.
- +12 more takeaways
TON Strategy Company Full Year 2025 Earnings Call - Staked Treasury Live, 219.7M TON Staked and $114.2M Crypto Reval Loss
TON Strategy Company spent 2025 building the plumbing for a simple promise, hold Toncoin, stake a large share, and grow TON per share inside a public company. The team launched staking in August, and ...
- Staking is live and material: 219.7 million TON were staked at year-end after staking began in August 2025.
- Staking produced 2.19 million TON in rewards since implementation, contributing roughly $4 million to 2025 revenue.
- Total revenue for 2025 rose to $12.8 million, up from $0.9 million in 2024, with staking part of that lift.
- +12 more takeaways